Small Cell Lung Cancer Clinical Trials 2018

Epub 2018 sep 25.

Small cell lung cancer clinical trials 2018.

In a large clinical trial treatment with the immunotherapy drug atezolizumab tecentriq combined with a standard chemotherapy regimen increased survival in patients with this highly aggressive form of lung cancer. Osimertinib is standard of care therapy for previously untreated epidermal growth factor receptor egfr mutation positive advanced non small cell lung cancer nsclc. The clinical trials on this list are for small cell lung cancer treatment. First line atezolizumab plus chemotherapy in extensive stage small cell lung cancer.

N engl j med. It explains areas of scientific research currently going on for small cell lung cancer. At least 1 prior regimen must have contained a platinum salt adjuvant therapy will constitute a prior treatment. Histologic or cytologic confirmed diagnosis of small cell lung cancer either limited or extensive disease at initial presentation is allowed.

However a phase 2 single group study of maintenance pembrolizumab and. Clinical trials look at new ways to prevent detect or treat disease. The next section in this guide is latest research. Consolidative radiotherapy for limited metastatic non small cell lung cancer.

Listing a study does not mean it has been evaluated by the u s. Evidence of progressive disease during or following 1 or 2 prior chemotherapy regimens. Clinical trials are research studies that involve people. Use the menu to choose a different section to read in this guide.

For the first time in more than two decades a treatment has been shown to improve how long patients with advanced small cell lung cancer sclc live. In this commentary we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer discuss challenges faced by regulatory agencies and highlight paradoxical lessons that emerge. Treatment patterns in advanced small cell lung cancer sclc the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Accelerated approvals may fail to expedite drugs to market in this setting and further research on overall survival benefit is needed to prove.

The efficacy and safety. Clinical activity of immunotherapies has been observed in patients with refractory or metastatic small cell lung cancer 8 12. All trials on the list are supported by nci.